Avondale Cuts Amedisys (AMED) to Underperform Following Q2 Results
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
An analyst at Avondale Partners downgraded shares of Amedisys (NASDAQ: AMED) from Market Perform to Market Underperform Wednesday morning following Q2 results from the company last night. The firm slashed its price target from $29 to $15.00.
Amedisys shares are down 2.8 percent to $21.96 this afternoon.
For more ratings news on Amedisys click here and for the rating history of Amedisys click here.
Amedisys shares are down 2.8 percent to $21.96 this afternoon.
For more ratings news on Amedisys click here and for the rating history of Amedisys click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marvell (MRVL) PT Raised to $225 at TD Cowen
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Evolution Petroleum launches stock offering to fund Permian Basin deal
Create E-mail Alert Related Categories
DowngradesRelated Entities
Avondale Partners, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
